BioPharmSignal logoBioPharmSignal

Biotech News

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

AngioDynamics (ANGO)AngioDynamicsCompany update

Investigator-Led Study Will Evaluate Imaging Biomarkers That May Help Predict Thrombectomy Success and Inform Long-Term PE Care LATHAM, N.Y. --(BUSINESS WIRE)--Oct. 2, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s

Related news

ANGOAngioDynamics2026-09-28 20:30 EST

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

ANGOAngioDynamics2026-07-28 12:30 EST

AngioDynamics to Participate in Upcoming Investor Conferences

LEGNLegend Biotech Corporation2026-09-10 12:00 EST

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

LEGNLegend Biotech Corporation2026-10-01 13:00 EST

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

IDYAIDEAYA Biosciences2026-09-28 10:00 EST

IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development

IARTIntegra LifeSciences2026-09-04 13:15 EST

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

IRTCiRhythm2026-10-05 13:05 EST

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

TEVATeva Pharmaceutical Industries2026-09-18 20:31 EST

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

TEVATeva Pharmaceutical Industries2026-09-16 12:00 EST

Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care

View all latest news

AngioDynamics

Vascular and Interventional Technology AngioDynamics develops medical technologies that restore blood flow, remove thrombus and treat selected tumors. Its portfolio is organized around higher-growth interventional platforms and a broader medical-device business. Mechanical Thrombectomy AlphaVac and AngioVac are mechanical aspiration...

Recent company news

ANGOAngioDynamics2026-10-02 10:00 EST

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

ANGOAngioDynamics2026-09-28 20:30 EST

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

ANGOAngioDynamics2026-07-28 12:30 EST

AngioDynamics to Participate in Upcoming Investor Conferences

ANGOAngioDynamics2026-07-14 10:00 EST

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

ANGOAngioDynamics2026-06-30 12:00 EST

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

Stock data

Close
15.12 USD
Market cap
453.68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States